Regulation of myeloid leukaemia by the cell-fate determinant Musashi

Takahiro Ito, Hyog Young Kwon, Bryan Zimdahl, Kendra L. Congdon, Jordan Blum, William E. Lento, Chen Zhao, Anand Lagoo, Gareth Gerrard, Letizia Foroni, John Goldman, Harriet Goh, Soo-Hyun Kim, Dong-Wook Kim, Charles Chuah, Vivian G. Oehler, Jerald P. Radich, Craig T. Jordan and Tannishtha Reya ()
Additional contact information
Takahiro Ito: Duke University Medical Center
Hyog Young Kwon: Duke University Medical Center
Bryan Zimdahl: Duke University Medical Center
Kendra L. Congdon: Duke University Medical Center
Jordan Blum: Duke University Medical Center
William E. Lento: Duke University Medical Center
Chen Zhao: Duke University Medical Center
Anand Lagoo: Duke University Medical Center
Gareth Gerrard: Imperial College London, Hammersmith Hospital
Letizia Foroni: Imperial College London, Hammersmith Hospital
John Goldman: Imperial College London, Hammersmith Hospital
Harriet Goh: Seoul St Mary’s Hospital, The Catholic University of Korea
Soo-Hyun Kim: Seoul St Mary’s Hospital, The Catholic University of Korea
Dong-Wook Kim: Seoul St Mary’s Hospital, The Catholic University of Korea
Charles Chuah: Singapore General Hospital, Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School
Vivian G. Oehler: Fred Hutchinson Cancer Research Center
Jerald P. Radich: Fred Hutchinson Cancer Research Center
Craig T. Jordan: James P. Wilmot Cancer Center, University of Rochester School of Medicine
Tannishtha Reya: Duke University Medical Center

Nature, 2010, vol. 466, issue 7307, 765-768

Abstract: Blocking leukaemia progress The molecular basis of the progression of chronic myeloid leukaemia from the chronic stage to the acute phase is poorly understood. Now, work in mouse models of chronic myeloid leukaemia shows that this progression is controlled by the cell fate regulator Musashi2, which in turn regulates Numb, Notch and p53 to block cellular differentiation. Musashi2 expression can be increased by aberrant transcription factors found in leukaemia and is observed during cancer progression in human patients with leukaemia, where it is associated with poorer prognosis. This raises the possibility that modulating Musashi–Numb associated signalling may serve as a new approach to therapies against this disease.

Date: 2010
References: Add references at CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://www.nature.com/articles/nature09171 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:466:y:2010:i:7307:d:10.1038_nature09171

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature09171

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().